Media stories about Cerus Corporation (NASDAQ:CERS) have been trending somewhat positive on Monday, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cerus Corporation earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.502110264094 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
CERS has been the subject of several research reports. Cantor Fitzgerald set a $7.00 price target on Cerus Corporation and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Zacks Investment Research raised Cerus Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. ValuEngine cut Cerus Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. BidaskClub lowered Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. Finally, BTIG Research restated a “buy” rating and set a $5.00 price objective on shares of Cerus Corporation in a research note on Sunday, May 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $7.25.
Cerus Corporation (CERS) traded down 1.90% during trading on Monday, reaching $2.58. The company’s stock had a trading volume of 666,295 shares. The company’s market cap is $281.57 million. The stock’s 50 day moving average is $2.50 and its 200 day moving average is $3.05. Cerus Corporation has a 12 month low of $1.93 and a 12 month high of $6.59.
Cerus Corporation (NASDAQ:CERS) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $9.53 million for the quarter, compared to the consensus estimate of $9.14 million. Cerus Corporation had a negative return on equity of 120.31% and a negative net margin of 164.39%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.18) earnings per share. On average, equities analysts expect that Cerus Corporation will post ($0.68) EPS for the current fiscal year.
In related news, insider Laurence M. Corash bought 92,796 shares of the company’s stock in a transaction on Friday, August 11th. The shares were purchased at an average price of $2.45 per share, for a total transaction of $227,350.20. Following the completion of the transaction, the insider now directly owns 1,375,711 shares in the company, valued at approximately $3,370,491.95. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 7.40% of the company’s stock.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.